A priority goal for next-generation COVID-19 vaccines is to reduce infection with and transmission of SARS-CoV-2 via the respiratory route, while maintaining or enhancing protection against symptomatic and severe disease. Utilization of mucosal vaccination to elicit robust mucosal immunity in the respiratory tract is a logical approach to achieving these goals.
Read More
VIEW ALL NEWS
![](https://ussfgmp.com/wp-content/uploads/2022/11/arrow_1.png)